Ovid Therapeutics Inc. (OVID)
Stock Price:
$5.37 USD
0.14 (2.68%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $5.38 +0.01 (0.19%) Oct 22, 6:03 PM
Key Info
| Market Cap |
340.10M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-76.19M |
| Shares Out |
63.33M |
| EPS (ttm) |
-1.54 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$5.37 |
| Previous Close |
$5.23 |
| Change ($) |
0.14 |
| Change (%) |
2.68% |
| Day's Open |
5.27 |
| Day's Range |
5.23 - 5.42 |
| Day's Volume |
336,572 |
| 52-Week Range |
1.80 - 9.40 |
More Stats
| Market Cap |
340.10M |
| Enterprise Value |
298.84M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
63.33M |
| Float |
38.36M |
| EPS (basic) |
-1.54 |
| EPS (diluted) |
-1.54 |
| FCF / Share |
-1.12 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.24M |
| Short Ratio |
5.95 |
| Short % of Float |
11.04% |
| Beta |
1.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
11.47 |
| Revenue |
n/a |
| Operating Income |
-77.47M |
| Net Income |
-76.19M |
| Free Cash Flow |
-62.10M |
| Net Cash |
41.25M |
| Net Cash / Share |
0.65 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-96.58% |
| ROE |
-200.70% |
| ROIC |
-877.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
7 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$14.83*
(176.16% upside)
Low
10.0
Current: $5.37
High
21.0
Target: 14.83
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -61.41 | -52.93 | -65.01 | -22.54 | -13.19 |
| Net Income | -60.46 | -51.98 | -64.81 | -22.41 | -13.16 |
| Shares Outstanding | 39.22 | 24.63 | 19.34 | 9.84 | 9.70 |
| Earnings Per Share | -1.54 | -2.11 | -3.35 | -2.28 | -1.36 |
| Operating Cash Flow | -51.09 | -45.56 | -31.47 | -17.80 | -5.49 |
| Capital Expenditures | -0.06 | -0.03 | -0.04 | -0.03 | -0.03 |
| Free Cash Flow | -51.15 | -45.59 | -31.51 | -17.83 | -5.52 |
| Cash & Equivalents | 76.74 | 41.50 | 87.13 | 51.94 | 69.94 |
| Net Cash / Debt | 76.74 | 41.50 | 87.13 | 51.94 | 69.94 |
| Assets | 80.84 | 47.65 | 89.46 | 53.03 | 70.38 |
| Liabilities | 10.82 | 8.84 | 6.02 | 3.73 | 2.31 |
| Book Value | 70.02 | 38.81 | 83.44 | 49.29 | 68.07 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Ovid Therapeutics Inc. |
| Country |
United States |
| Employees |
60 |
| CEO |
Jeremy Max Levin |
Stock Information
| Ticker Symbol |
OVID |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: OVID |
| IPO Date |
May 5, 2017 |
Description
Ovid Therapeutics, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which is in a Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; and OV881 as a microRNA gene therapy for the treatment of angelman syndrome. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop, manufacture and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was founded in 2014 and is headquartered in New York, New York.